Compare DexCom, Inc. (DXCM) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs YieldMax NVDA Option Income Strategy ETF — how do they compare? DexCom, Inc. trades at $77.86 (market cap $28.06B), while YieldMax NVDA Option Income Strategy ETF trades at $12.59. The key difference: DexCom, Inc. is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | NVDY | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $89.53 | $17.96 |
52-Week Low | $54.84 | $12.03 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $12.60, down 1.56% with a mixed technical outlook showing bullish overall signals but bearish moving averages. The ETF generates weekly income through NVIDIA option strategies, with recent distributions ranging from $0.10-$0.21 per share. Technical analysis indicates support at $12-$13 levels while fundamental metrics remain unavailable for this income-focused strategy.
The ETF offers high-income potential through systematic option selling on NVIDIA shares but sacrifices significant upside participation. Recent articles highlight the trade-off between income generation and missed NVIDIA gains, with the 1.09% management fee impacting returns. Key risks include NVIDIA volatility exposure and the strategy's capped upside during strong market moves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
